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FK 506 (Tanolimus. Prograf'") has been recently ap-proved by the Food and Drug Administration (FDA) 
for baseline immunosuppression following orthotopic liver 
transplantation (OLT). The drug was first used clinically in 
1989. 1 and I year later at the Thirteenth International 
Congress of Transplantation Society. San Francisco. CA 
1990. extensive reports were given from our center describ-
ing the potential value of this drug in clinical transplanta-
tionK~·D We have so far treated 1497 primary liver transplant 
recipients with FK 506 and an additional 512 patients who 
were converted to FK 506 from cyclosporine (CyA). This 
report will focus on the first 1000 consecutive primary OL Ts 
in the series. The parameters examined were patient and 
graft survival. causes of death and retransplant. etfect of 
age. United Network for Organ Sharing (liNOS) status. 
level of maintenance immunosuppression. and adverse 
events. 
MATERIALS AND METHODS 
Cases accrued between August I':IS9 and December 1992. There 
were om male and 400 female patlcnts. Mean age was 42.6 :: 20.2 
years. One hfth of all patients were older than flO years and 7.5'7" 
were younger than 2 \'ears. Mean follow-up was 39.5 (range 19 to 
59) months. The age group distribution and indications for liver 
transplantation are shown in Tables I and 2. n:spectivelv. One 
hundred hfty-nme patients (15.9r;.) were UNOS class 1 and:' (nut 
"I' hospital with limltcd working capacltv). JX2 patients (JS.2\{) 
wen: class J (in the hospital). 32S (32.S";' \ were class 4 (in intensive 
Table 1. Distribution of Patients as Per Age and UNOS 
Mean 
Age IYI Age n 1%) 
Infants '2 0.95 75 (7.5) 
Children 2 '" 18 9.2 91 (9.1) 
Adults ·18 ~SM 45.2 630 (63.0) 
Semors 60 64.8 204 (20.4) 
Table 2. Indications for Transplants 
Nonalcoholic cirrhosis 
Alcoholic cirrhOSiS 
Biliary atresia 
Primary biliary cirrhosiS 
Primary sclerosing cholangitis 
Primary hepatiC malignancy 
Acute fulminant failure 
Miscellaneous 
Total 
n (%) 
341 (34.1) 
188 (18.8) 
86 (8.6) 
83 (8.3) 
60(6.0) 
79 (7.9) 
34 (3.4) 
129 (12.9) 
1000 
~are unit [ICUll. and 131 (13.le;,) were UNOS 4 STAT (life 
expectancy <:! days in the ICU). Two hundred seventy donors were 
younger than IS years (ml!an l) ::: 2). 347 were IX or older but 
younger than 35 (mean 25 ::: 2\ years. 242 were 35 or older but 
younger than:iO (mean 42::: -1) Years. and loll were older than 50 
I mean 57 :: 4) years of age at the time of primary transplant. 
Immunosuppression 
FK 506 was begun IV on the dav of operation and converted to oral 
dosing when bowel function returned. The current IV dose is 0.05 
mg;kg/d for adults and seniors. 0.1 mg;kg/d for children and infants. 
less than one half of what was given in 19S9 and carly 1990. The 
heginning oral doses averaged 0.2 ::: 0.1 mg;kg;d. However. dose 
adjustments were made continuously. gUided by plasma trough 
Il!vels of FK 506 (targeted at 1.0 ng;mLl and ahove all hy the 
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Table 3. Indications for Retransplantation and infants received SOO mg hydrocortisone instead of methylpred-
ntsone. 
Primary nonfunction 
Vascular complications 
Ischemic Inlury 
Rejection 
Biliary complication 
Recurrence of disease 
Miscellaneous 
Total 
n 1%) 
53 (4.6) 
45 (3.9) 
16 (1.4) 
13 (1.1) 
6 (0.5) 
5 (0.5) 
9(0.8) 
14712.8 
RESULTS 
Retransplantation 
balance of rejection control. signs of nephrotoxicity. neurotoxicity. 
and diabetogenicity. In the initial part of the trial. 63 patients 
received I g methylprednisone followed by a 5-day methylpred-
nisolone burst. beginning at 200 mg on day 1. and ending with a 
maintenance dose of 20 mg/d. In the middle part of the trial. this 
steroid bolus was omitted. Children received I g hydrocortisone 
A total of 1147 transplants were performed on the lOlli, 
patients during the period of study. A single retransplanta-
tion was performed on 118 (11.8%) of the patients. fK~ 
(1.3%) required three. and 1 (who is alive) underwent 4 
transplants. The retransplantation rate was 9.3% for in-
fants, 12.1% for children. 14.3% for adults. and 11.8% for 
seniors. The overall rate was 13.2%. The indications for 
retransplantation are shown in Table 3. 
Survival 
Patients. The overall actual patient survival at 1 year was 
83.1 % and the 4-year actuarial survival rate was 73.4% (Fig 
Fig 1. (A) Patient and graft 
survival over the 5-year post-
transplantation penod. (8) Pa-
tient survival by age group of 
the reCIpients at the time of first 
transplant. 
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IA). Differences in patient survival for different age groups 
was statisticallv significant (P < .0001 by log rank test: Fig 
IB). The best results were with patients older than 2 but 
who were 18 vears or younger with actual 3-month and 
l2-month survival rates of 92.3% and 91.2'70. respec-
tively. Taking the adult age group as the reference. the 
risk of mortality was 1.55 (lower 1.17. upper 2.07. P = 
.003) for seniors. 0.34 (lower 0.17. upper 0.7, P = .(03) 
for children. and 0.89 (lower 0.53. upper 1.5. P = .67) for 
infants. Similarly, taking UNOS status 3 group as a 
reference. the relative risk of mortality at 95% confi-
dence interval. for UNOS 4 was 1.56 (lower 1.15. upper 
2.12. P = .004) and for UNOS 4 STAT was 1.71 (lower 
1.18, upper 2.5: P = .005). However, there was no 
significant difference for UNOS status 1 and 2 taking 
UNOS 3 as a reference group. 
Grafts. The overall actual graft survival rate for I year 
was 72.2S: and actuarial 4-year graft survival rate was 
0,1.0 
" 0 . .15 
" 
" 0 . .10 
" 
,. 
" 
,. 
" 
.... 
" 
>. 0.25 
" t'lI 
"0 020 
-Cl 
" 
Table 4. Causes of Death (n = 245) 
Infection 
Bacterial 
Fungal 
Viral 
Other 
Cardiopulmonary 
n 1%) 
93 (38) 
60 (24) 
21 (9) 
4 (2) 
8 (3) 
36 (15) 
Malignancy 
Primary nonfunction 
Technical 
Multisystem failure 
Intracranial 
Miscellaneous 
1101 
n (%) 
29 (12) 
23 (9) 
8 (3) 
8 (3) 
6 (2) 
42 (17) 
64.1 %. The effect of the UNOS urgency status and age 
factors was similar to that on patient survival. 
Causes of Death 
A total of 245 patients died in the follow-up period of 19 to 
59 months. Their causes of death are shown in Table 4. 
Infection was the most common cause of death. 
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Fig 2. Mean FK 506 dose (mgl 
kg/d) by age (top) and median 
FK 506 plasma trough level by 
age (bottom). 
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Fig 3. (Top) Steroid dose varying from O. :s;5. >5. :s;10. >10 at 
various time pOints. (Bottom) Freedom of steroids for various 
age groups at various time points from the time of transplant. 
Maintenance Immunosuppression 
FK 506. The FK 506 doses steadily declined with time in 
all age groups (except in infants) (Fig 2. top). along with a 
decrease in average plasma trough levels (Fig 2. bottom). 
Predllisolle. By 3 months. 53% of surviving patients were 
steroid frce and at ~ years this had increased to 69%. For 
those on steroids at these milestones. the doses were low. 
only lor,. and 6r ;. of the patients requiring more than 10 
mgtd at 3 months and ~ years. respectively. Infants and 
l:hildren were weaned otf steroids much faster than adults 
and seniors (Fig 3). 
Organ Function 
Lirer AI/ograji. liver function tests are summarized in 
Fig 4A. B. The slight upward shift in aspartate transaminase 
(AST). alanine transaminase (ALT). and gamma glutamyl 
transpeptidase (GGTP) at 4 years was related to recurrence 
of hepatitis in some of the patients. 
KidIlL'\' FIII/criol/. Mean serum creatinine and blood urea 
nitro!!en (BUN) levels were elevated at 3 months. but were 
stable thereafter during the entire follow·up period (Fig ole. 
D). 
Rejection 
The tirst 123 adults and seniors have now completed 4 years 
of follow-up. allowing the precise study of rejection accrual: 
first.' months 42':;.:; to 12 months IX0-. 12 to O~ months 
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17%. 24 to 36 months 4%. and 36 to 48 months 3%. 
Rejection after 3 months was mild and easily reversible. 
Onlv 6 (0.5%) of the 1147 grafts were lost due to acute 
rejecti~n in the entire study. 3 in the learning phase of the 
trial. Interestingly. the majority of these patients had a 
strongly positive lymphocytic crossmatch. an adverse factor 
also previously noted in CyA-treated liver recipients.1> 
Adverse Events 
Renal. Nephrotoxicity. the subject of a vast literature 
review. was already well characterized by 1990.2- 4.7 Only 
more subtle manifestations are considered here. Hyperkal-
emia was the most common adverse event and was seen in 
41.6%,46.0%.46.9%. and 44.6% of patients at 1.2.3, and 
4 years posttransplant respectively. which was easily con-
trolled with 0.1 to 0.2 mwd of fludrocortisone. Hyperten-
sion requiring one (usually) or more antihypertensive med-
ications was observed in 28.7%. 33.6%. 37.0%. and 38.5% 
of patients at 1. 2. 3. and 4 years. respectively. This was not 
the true incidence of de novo hypertension. for it included 
many patients who were hypertensive preoperatively. 
.\letabolic. The incidence of insulin-dependent diabetes 
was 16.2%. 13.0%. 12.8%, and 14.4% at 1.2.3. and 4 years. 
respectively. including an estimated 5% of patients who 
were already on insulin before transplantation. Median 
serum cholesterol concentrations were 149. 147. 159. and 
158 mwdL at I, 2. 3. and 4 years. respectively. 
Neurologic. Seizure activity or other major neurologic 
complications occurred in 7.06% of patients. which were 
almost always dose related and reversible with reductions in 
immunosuppression. 
Infections. Significant bacterial. viral. or fungal infections 
were recorded at a 36%. 26%. 22%. and 10% incidence. 
respectively. during the 4-year follow-up. 
PostTransplallt Lymphoproliferatil'e Disorder (PTLD). 
The total incidence over the first 4 years was 3.95c'c. which 
was highest in children. More than one half of these cases 
were infectious mononucleosis syndrome which responded 
to reduction in immunosuppression. The spcctrum of this 
syndrome has been extensively reportedH and is not drug 
specific. 
DISCUSSION 
The reports from Pittsburgh of 19!W·<J·1U and those from 
the 13th International Congress of the Transplantation 
Society held in San Francisco;-u have been contirmed in a 
recently published analysis of the European multicenter 
randomized trial comparing FK 506 and CyA for OlT." 
The advantages of this drug over CyA include a reduction in 
acute. refractory acute. and chronic rejection episodes and 
the ability to achieve this ohjective with smaller require-
ments of corticosteroids. No side etfects uniquely attribut-
able to FK 506 have emerged. Patient survival and graft 
survival rates in the European trial were 5.5 r;. and 4.9r;,. 
respectively. which were heuer than that in the alternative 
Ireatment group. Results from the American multicenter 
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t rial have not vet been published. but early data suggest that 
FK 506 has at least equivalent efficacy to CyA. 
I n our current study. there was an unusually large num· 
her of patients in the high urgency UNOS categories 3 and 
4 and of recipients (20AC:r ) above the age of 60 years. 
Furthermore. many of the more seriously ill as well as the 
older patients had been rejected as transplant candidates at 
Dther centers and most as well as infants and children were 
excluded from the American multicenter trial. These 
groups arc thought to be selectively helped by FK 5U6 
hecause of the ability to minimize steroid ust!. Includt!d also 
in our study were 34 (304£';') patients with acute fulminant 
failure and 79 (7.lY'r) with primary hepatic malignancy. 
Because of the dt!epening organ shortage. 16£'" of the adults 
and seniors received their tirst organ grafts from donors 
lwer the age of 50 years (mean 57 :: ()). auuing to the 
hazard as reported separatc!v at this meeting by Marino et 
al. 12 
Freedom from hirsutism. gingival hyperplasia. and ste-
roid stigmata contributed to a good quality of life. Neph-
rotoxicity was the most serious side clrcct during the 
learning phase. [.' hut With downward dose adjustments. this 
was not significantly different than with previous immuno-
suppressive regimens nor was a trend observed. The com-
plications of infections. I'TLD. diabetes. and neurologic 
syndromes also were comparable to past regimens. Hyper-
tension and hypercholesterolemia were less frequent and 
severe. 
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